D
David G. Tubergen
Researcher at University of Texas MD Anderson Cancer Center
Publications - 22
Citations - 1126
David G. Tubergen is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Acute lymphocytic leukemia & Cancer. The author has an hindex of 15, co-authored 22 publications receiving 1109 citations. Previous affiliations of David G. Tubergen include University of Minnesota & Medical College of Wisconsin.
Papers
More filters
Journal ArticleDOI
Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity.
Mark Fishaut,Mark Fishaut,David G. Tubergen,David G. Tubergen,Kenneth McIntosh,Kenneth McIntosh +5 more
Journal ArticleDOI
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
David G. Tubergen,Clinton F. Stewart,Charles B. Pratt,William C. Zamboni,Naomi J. Winick,Victor M. Santana,Zo Anne Dryer,Joanne Kurtzberg,Beverly Bell,Holcombe E. Grier,Teresa J. Vietti +10 more
TL;DR: In heavily pretreated children, the maximum tolerated dose (MTD) for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/ m2/day with GCSK, and the dose-limiting toxicity is hematopoietic.
Journal ArticleDOI
Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group
Fatih M. Uckun,Harland N. Sather,Paul S. Gaynon,Diane C. Arthur,Michael E. Trigg,David G. Tubergen,James B. Nachman,Peter G. Steinherz,Martha G. Sensel,Gregory H. Reaman +9 more
TL;DR: Patients with My+ ALL have similar treatment outcomes as My- ALL patients, independent of treatment risk category, demonstrating that myeloid antigen expression was not an adverse prognostic factor for childhood ALL.
Journal ArticleDOI
Pharmacokinetics and Pharmacodynamics of Oral Methotrexate and Mercaptopurine in Children With Lower Risk Acute Lymphoblastic Leukemia: A Joint Children’s Cancer Group and Pediatric Oncology Branch Study
Frank M. Balis,John S. Holcenberg,David G. Poplack,Jeffrey Ge,Harland N. Sather,Robert F. Murphy,Matthew M. Ames,Mary J. Waskerwitz,David G. Tubergen,Solomon Zimm,Gerald S. Gilchrist,W. Archie Bleyer +11 more
TL;DR: Methotrexate and mercaptopurine plasma concentrations and erythrocyte thioguanine nucleotide levels were highly variable, but measurement of these pharmacokinetic parameters at the start of maintenance will not distinguish patients who are more likely to relapse.
Journal ArticleDOI
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
David G. Tubergen,Mark Krailo,Anna T. Meadows,Jeffrey G. Rosenstock,Marshall E. Kadin,Margaret Morse,Denis R. King,Peter G. Steinherz,John H. Kersey +8 more
TL;DR: Long-term EFS in children with LB NHL can be achieved in the majority of patients, and addition of DAUN and L-ASP to the COMP regimen does not produce a more effective treatment than LSA2L2.